MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Evaluation of the Clinical Efficacy of Motivational System Training in Parkinson’s disease

T. Chomiak, A. Watts, S. Tan, M. McKeown, B. Hu (Calgary, AB, Canada)

Meeting: 2018 International Congress

Abstract Number: 1155

Keywords: Rehabilitation

Session Information

Date: Sunday, October 7, 2018

Session Title: Technology

Session Time: 1:45pm-3:15pm

Location: Hall 3FG

Objective: This study investigated whether Ambulosono motivational training could lead to clinically important improvements in motor function in Parkinson’s disease (PD).

Background: Declining motivational vigour is a key mechanism underlying PD. Ambulosono is a motivational walking program designed to achieve sustained motivational system activation over long distance ambulation in a naturalistic environment. During Ambulosono, a wearable device contingently links the user’s step amplitude to pleasurable music play. Uninterrupted music delivery requires an enduring level of mental and physical vigour to maintain step initiation, amplitude, and walking speed.

Methods: We prospectively monitored changes in UPDRS-III score among 54 Ambulosono users from two academic centers (mean disease duration = 7.3 years). Covariate adjusted Ambulosono usage information was used for clustering users into different Ambulosono “dosing” groups. UPDRS-III score changes were compared with the benchmark threshold of minimum clinical important difference (CID) (i.e. annual increase of 2.5 points).

Results: The average UPDRS-III score in our study population, assessed over 16.6 months, decreased by -0.3 points, significantly lower than the CID threshold (p<0.05). Sub-group analysis showed that in nearly 40% of patients who belonged to high dosage users, i.e. a group average of about 146 walks, 89 hours of training, and 9.2 walks/month over 15.6 months, their mean UPDRS-III score decreased by just over -3 points over a 13.4 month period (p<0.05), significantly better than both baseline scores and the CID benchmark. These patients had greater motor impairment at baseline and tended to be have a longer disease duration than other users. In <10% of high dosage users, UPDRS-III scores exhibited the expected annual increase. Ambulosono low dosage users comprised roughly 45% of study patients who had on average around 45 walks, 23 hours of training, and 2.4 walks/month over a 17.6 month period. Their UPDRS-III scores showed no significant decline or CID during follow-up.

Conclusions: Ambulosono is a safe home-based exercise program, well suited for patients with PD. A Randomized Control Trial is warranted to further determine whether targeted motivational system training can indeed produce clinically important improvements in a larger patient population.

To cite this abstract in AMA style:

T. Chomiak, A. Watts, S. Tan, M. McKeown, B. Hu. Evaluation of the Clinical Efficacy of Motivational System Training in Parkinson’s disease [abstract]. Mov Disord. 2018; 33 (suppl 2). https://www.mdsabstracts.org/abstract/evaluation-of-the-clinical-efficacy-of-motivational-system-training-in-parkinsons-disease/. Accessed June 14, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/evaluation-of-the-clinical-efficacy-of-motivational-system-training-in-parkinsons-disease/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Humor processing is affected by Parkinson’s disease and levodopa
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley